TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25083010

Group type: EXPERIMENTAL
Intervention: Professionally administered CBT‐I (PCBT‐I; n = 81)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Video-based CBT‐I (VCBT‐I; n = 80)
Number of subjects: 242

Group type: COMPARATOR
Intervention: No treatment (CTL; n = 81)
Number of subjects: 242
Study: 22409766

Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) program for 5 weeks
Number of subjects: 0
Study: 20840188

Group type: EXPERIMENTAL
Intervention: Contingent condition (voucher-based CM)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Non-contingent condition
Number of subjects: 166
Study: 17356993

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone with 20 minutes counseling and weekly visits
Number of subjects: 142

Group type: COMPARATOR
Intervention: Buprenorphine/naloxone with 45 minutes counseling and thrice weekly visits
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Overall satisfaction score
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Medication and ancillary services
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Interactions with other opioid-dependent patients and referrals to Narcotics Anonymous
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Female gender and non-White ethnicity/race
Number of subjects: 142
Study: 15732027

Group type: EXPERIMENTAL
Intervention: Anemic patients in the IN‐CHF Registry
Number of subjects: 7411

Group type: COMPARATOR
Intervention: Patients without anemia in the IN‐CHF Registry
Number of subjects: 7411

Group type: EXPERIMENTAL
Intervention: Anemic patients in the Val‐HeFT trial
Number of subjects: 7411

Group type: COMPARATOR
Intervention: Patients without anemia in the Val‐HeFT trial
Number of subjects: 7411
Study: 12352161

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced magnetic resonance angiography (CE-MRA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Digital subtraction angiography (x-ray DSA)
Number of subjects: 43
Study: 10429837

Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg from the Diskhaler
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg from the prototype device
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Overall inhalation of zanamivir
Number of subjects: 13
Study: 7591715

Group type: EXPERIMENTAL
Intervention: Intravenous betahistine (57, 114, and 285 micrograms i.d.)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral betahistine plus cetirizine and cimetidine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Histamine (1 microgram i.d.)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral betahistine alone
Number of subjects: 11
Study: 2124446

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug for a mean period of 6 weeks (range: 3‐12 weeks)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Group I (n = 61) with a percentage of pathological DBP readings greater than 90 mmHg during daytime as high as 50% or more
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Group II (n = 41) with a percentage of pathological DBP readings less than 50%
Number of subjects: 102
Study: 7447225

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cholesterol-lowering diet
Number of subjects: 0
Study: 30548458

Group type: EXPERIMENTAL
Intervention: Mentee-reported relationship quality
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Mentor-reported use of goal-setting and feedback-oriented activities
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Interaction between relationship quality and goal-setting/feedback activities
Number of subjects: 1360
Study: 29173856

Group type: EXPERIMENTAL
Intervention: Essix retainers
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Wrap-around retainers
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Combination of fixed retainers and Essix
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (normal occlusion)
Number of subjects: 176
Study: 27392196

Group type: EXPERIMENTAL
Intervention: 8-week family-based healthy lifestyle intervention
Number of subjects: 70
Study: 23990233

Group type: EXPERIMENTAL
Intervention: Adenosine (2 mg + 2 mg) administered during PCI
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 22250038

Group type: EXPERIMENTAL
Intervention: Formoterol (24 µg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 µg)
Number of subjects: 8
Study: 19583040

Group type: EXPERIMENTAL
Intervention: Carisolv chemo‐mechanical technique and Duraphat (2.23% F) fluoride varnish
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Duraphat alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stannous fluoride solution (8%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: All groups (Carisolv/Duraphat, Duraphat, Stannous fluoride)
Number of subjects: 40
Study: 17325272

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein (LDL) levels above individual preadmission LDL goals as defined by NCEP-ATPIII guidelines
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Previously diagnosed dyslipidemia
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Lipid-lowering agents (LLA)
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Lipid-lowering agents (LLA) indicated
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Lower LDL therapeutic targets
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Preadmission LLA
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Calendar time
Number of subjects: 1040
Study: 16960636

Group type: EXPERIMENTAL
Intervention: Infrared therapy (IR therapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 40
Study: 14691360

Group type: EXPERIMENTAL
Intervention: Individual cognitive‐behavioral family‐based therapy (CBFT)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Group cognitive‐behavioral family‐based therapy (CBFT)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 77
Study: 11054434

Group type: EXPERIMENTAL
Intervention: Renal function-based dosing
Number of subjects: 38

Group type: COMPARATOR
Intervention: Surface area-based dosing
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC
Number of subjects: 38
Study: 8972014

Group type: EXPERIMENTAL
Intervention: Clopidogrel at doses of 10, 25, 50, 75 or 100 mg OD
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ticlopidine 250 mg BID
Number of subjects: 150
Study: 1738517

Group type: EXPERIMENTAL
Intervention: Hydrogel pessary containing 10 mg of prostaglandin E2
Number of subjects: 215
Study: 6824553

Group type: EXPERIMENTAL
Intervention: mianserin 30 mg at night
Number of subjects: 58

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 58
Study: 31553945

Group type: EXPERIMENTAL
Intervention: Walking School Bus (WSB) program
Number of subjects: 45
Study: 29048206

Group type: COMPARATOR
Intervention: 3500 Shock Waves Per Session (SWPS) in Group A
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: 7000 Shock Waves Per Session (SWPS) in Group B
Number of subjects: 307
Study: 28929669

Group type: EXPERIMENTAL
Intervention: Modified Chaiping decoction (6 doses per week, one dose every day in two times by oral administration)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Modified Chaiping decoction
Number of subjects: 119
Study: 25081808

Group type: EXPERIMENTAL
Intervention: Daily weight tracking for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Weekly weight tracking for 6 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Daily weight tracking
Number of subjects: 30

Group type: COMPARATOR
Intervention: Weekly weight tracking
Number of subjects: 30
Study: 22539020

Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg daily for 12 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 19411519

Group type: EXPERIMENTAL
Intervention: Etched only the enamel (group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Etched both enamel and dentin (group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall retention rate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 100
Study: 17207911

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GC)
Number of subjects: 110
Study: 14747389

Group type: EXPERIMENTAL
Intervention: 1 mg folic acid
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: 15 mg folic acid
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: High baseline tHcy (quartiles)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: High-dose folic acid (all groups combined)
Number of subjects: 510
Study: 11259518

Group type: EXPERIMENTAL
Intervention: Coping skills intervention (daily practice with audiotaped instructions)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard care control condition
Number of subjects: 46
Study: 9676351

Group type: EXPERIMENTAL
Intervention: Bronchoretard Capsules
Number of subjects: 19

Group type: COMPARATOR
Intervention: Capsule formulation from the US market
Number of subjects: 19
Study: 7990375

Group type: EXPERIMENTAL
Intervention: Veroshpiron (50-100 mg/day)
Number of subjects: 39
Study: 2904461

Group type: EXPERIMENTAL
Intervention: Mezlocillin alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefuroxime and metronidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical placebo controls
Number of subjects: 0
Study: 29554321

Group type: EXPERIMENTAL
Intervention: Repeated frameless robotic SRS based on SPACE imaging sequence
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Repeated frameless robotic SRS based on MPRAGE imaging sequence
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Overall survival assessment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Quality of life and neurocognition evaluation every 3 months using CANTAB tests and EORTC questionnaires
Number of subjects: 200
Study: 27393707

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen mixture
Number of subjects: 0
Study: 24998619

Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 35
Study: 23117488

Group type: EXPERIMENTAL
Intervention: Graduated Compression Stockings (GCS)
Number of subjects: 1971

Group type: COMPARATOR
Intervention: DVT rates
Number of subjects: 1971
Study: 21628668

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 569

Group type: COMPARATOR
Intervention: Atazanavir-ritonavir
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: X4 viruses
Number of subjects: 569

Group type: COMPARATOR
Intervention: R5 strains
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: CD4 cell count recovery
Number of subjects: 569
Study: 19180852

Group type: EXPERIMENTAL
Intervention: Fully trained group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Minimally trained group
Number of subjects: 20
Study: 18250489

Group type: EXPERIMENTAL
Intervention: Taliton (carvedilol) starting dose 3.125 mg twice daily, increased to target dose 25 mg twice daily over 6 months
Number of subjects: 20
Study: 15564697

Group type: EXPERIMENTAL
Intervention: Bepridil (200 mg/day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bepridil (200 mg/day) + Aprindine (40 or 60 mg/day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bepridil + Aprindine
Number of subjects: 23
Study: 12775190

Group type: EXPERIMENTAL
Intervention: Patients with orbitofrontal lesions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with damage to the dorsolateral prefrontal cortex
Number of subjects: 0
Study: 10365144

Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy including interferon-alpha 2a, interleukin-2, 5-fluorouracil (5-FU), isotretinoin (ISO), and vinblastin (VBL)
Number of subjects: 0
Study: 7673284

Group type: EXPERIMENTAL
Intervention: Postoperative blood salvage using the Autovac Postoperative Orthopaedic Autotransfusion Canister
Number of subjects: 232

Group type: COMPARATOR
Intervention: Closed suction drainage using the Hemovac system
Number of subjects: 232
Study: 1967561

Group type: EXPERIMENTAL
Intervention: Xamoterol 200 mg b.i.d. for 3 months
Number of subjects: 617

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Digoxin 0.125 mg b.i.d.
Number of subjects: 617
Study: 7375188

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 29343201

Group type: EXPERIMENTAL
Intervention: Blackcurrant juice (500 mg of polyphenols)
Number of subjects: 9
Study: 28825235

Group type: EXPERIMENTAL
Intervention: Ethyl chloride aerosol spray (n=66)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo aerosol spray (n=60)
Number of subjects: 126
Study: 26074365

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) administered through a buccal window approach
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional management via creation of a window on the buccal wall and curettage of the walls of the defect
Number of subjects: 24
Study: 25309087

Group type: EXPERIMENTAL
Intervention: Aconite cake‐separated moxibustion (1 cone, 3 treatments/week)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Aconite cake‐separated moxibustion (2 cones, 3 treatments/week)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Aconite cake‐separated moxibustion (1 cone, 6 treatments/week)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Aconite cake‐separated moxibustion (2 cones, 6 treatments/week)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Aconite cake‐separated moxibustion (frequency comparison)
Number of subjects: 166
Study: 20937671

Group type: EXPERIMENTAL
Intervention: Rituximab 2×1000 mg + MTX
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Rituximab 2×500 mg + MTX
Number of subjects: 755

Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 755
Study: 19374299

Group type: EXPERIMENTAL
Intervention: 6-strand hamstring tendons
Number of subjects: 34

Group type: COMPARATOR
Intervention: bone-patellar tendon-bone graft
Number of subjects: 34
Study: 17305661

Group type: EXPERIMENTAL
Intervention: Prednisolone 1 mg/kg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.15 mg/kg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Dexamethasone 0.6 mg/kg
Number of subjects: 99
Study: 15665624

Group type: EXPERIMENTAL
Intervention: Individualized adjuvant peptide vaccinations derived from MelanA/MART1, gp100, and tyrosinase with GM-CSF
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Individualized adjuvant peptide vaccinations with GM-CSF
Number of subjects: 10
Study: 11391090

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 9281928

Group type: EXPERIMENTAL
Intervention: Rest (napping)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Sensory stimuli
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Perceptions of odors
Number of subjects: 124
Study: 8471126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3086989

Group type: EXPERIMENTAL
Intervention: Transgrow culture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gonozyme test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thayer-Martin cultures
Number of subjects: 0
Study: 30353706

Group type: EXPERIMENTAL
Intervention: 5 lb weight gain over 7 days
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Increased dyspnoea over 7 days
Number of subjects: 119
Study: 28969699

Group type: EXPERIMENTAL
Intervention: Triheptanoin
Number of subjects: 10
Study: 26499966

Group type: EXPERIMENTAL
Intervention: Alive‐PD intervention
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group (6-month wait-list usual-care)
Number of subjects: 339
Study: 23639624

Group type: EXPERIMENTAL
Intervention: CRT-D with slow VT
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: CRT-D with fast VT/VF
Number of subjects: 426

Group type: COMPARATOR
Intervention: ICD patients
Number of subjects: 426
Study: 21247664

Group type: EXPERIMENTAL
Intervention: Aquaphor Healing Ointment (AHO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Biafine Topical Emulsion (BTE)
Number of subjects: 20
Study: 19556227

Group type: EXPERIMENTAL
Intervention: Baseline measurement of elasticity and stiffness using echo-tracking ultrasound system (Diamove)
Number of subjects: 61
Study: 17628972

Group type: EXPERIMENTAL
Intervention: AR group (with allergic rhinitis)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: NAR group (without allergic rhinitis)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: AR group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: NAR group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: GATA-3 positive-staining rate
Number of subjects: 56
Study: 15117996

Group type: EXPERIMENTAL
Intervention: Acupuncture twice per week for 4 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Acupuncture once per week for 6 weeks
Number of subjects: 31
Study: 11451008

Group type: EXPERIMENTAL
Intervention: RPU + TIAR
Number of subjects: 380

Group type: COMPARATOR
Intervention: RPU alone
Number of subjects: 380
Study: 9012642

Group type: EXPERIMENTAL
Intervention: E4 allele carriers
Number of subjects: 260

Group type: COMPARATOR
Intervention: E2 allele carriers
Number of subjects: 260

Group type: COMPARATOR
Intervention: E3 allele carriers
Number of subjects: 260
Study: 7970216

Group type: EXPERIMENTAL
Intervention: Apolipoprotein E epsilon 4 allele
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Apolipoprotein E epsilon 4 homozygote
Number of subjects: 88
Study: 3475231

Group type: EXPERIMENTAL
Intervention: 1 mg or 2 mg PGE2 intravaginally at an interval of 6 hours
Number of subjects: 99

Group type: COMPARATOR
Intervention: Intravenous oxytocin and amniotomy
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PGE2 induction
Number of subjects: 99

Group type: COMPARATOR
Intervention: Oxytocin group
Number of subjects: 99
Study: 2129320

Group type: EXPERIMENTAL
Intervention: pravastatin 20 mg b.i.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: cholestyramine 16‐24 g/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: control group (age‐ and sex‐matched)
Number of subjects: 20
Study: 973981

Group type: EXPERIMENTAL
Intervention: Diazepam (5-10 mg three times daily)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Thioridazine (25-50 mg three times daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30337697

Group type: EXPERIMENTAL
Intervention: FBA
Number of subjects: 111

Group type: COMPARATOR
Intervention: BuCy2
Number of subjects: 111
Study: 27842179

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan 97/103 mg twice daily
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Enalapril 10 mg twice daily
Number of subjects: 8399

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan 97/103 mg twice daily (newly started MRA)
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Enalapril 10 mg twice daily (newly started MRA)
Number of subjects: 8399
Study: 26291258

Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide (20mg/ml)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Keloid excisions without triamcinolone
Number of subjects: 15
Study: 24010637

Group type: EXPERIMENTAL
Intervention: Risedronate plus calcium and vitamin D
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo plus calcium and vitamin D
Number of subjects: 80
Study: 21784746

Group type: EXPERIMENTAL
Intervention: Pre-selected ventricular tachyarrhythmia detection, anti-tachycardia pacing, and SVT discriminator parameters
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Standard arrhythmia detection and therapy approaches (Control group)
Number of subjects: 1600
Study: 20143017

Group type: EXPERIMENTAL
Intervention: Extraction group (first premolar extraction)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-extraction group
Number of subjects: 120
Study: 16565252

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO) treatment to normalize hemoglobin (Hgb) levels.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO) treatment to achieve Hgb >12 g/dl.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO) treatment to achieve Hgb >11 g/dl.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (EPO) treatment for normalization of hematocrit.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO) treatment.
Number of subjects: 0
Study: 14730403

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 19

Group type: COMPARATOR
Intervention: (111)In-granulocyte scintigraphy
Number of subjects: 19
Study: 11158750

Group type: EXPERIMENTAL
Intervention: Clinafloxacin
Number of subjects: 409

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 409
Study: 9279532

Group type: EXPERIMENTAL
Intervention: Octreotide 25 micrograms subcutaneously (s.c.)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7848391

Group type: EXPERIMENTAL
Intervention: Cephalad catheter insertion (group 1)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Caudad catheter insertion (group 2)
Number of subjects: 105
Study: 3774016

Group type: EXPERIMENTAL
Intervention: Adjuvant combination chemotherapy with low-dose prednisone (7.5 mg/day) and CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: CMFp + T (chemotherapy plus low-dose prednisone and tamoxifen)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Endocrine therapy alone (p + T)
Number of subjects: 491

Group type: COMPARATOR
Intervention: No further treatment after total mastectomy and axillary clearance (observation group)
Number of subjects: 491
Study: 30064926

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 1215
Study: 28815256

Group type: EXPERIMENTAL
Intervention: Ibuprofen capsules
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 500